Literature DB >> 10233943

A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice.

M Singh1, R Cattaneo, M A Billeter.   

Abstract

It has been shown previously that measles virus (MV) can be successfully used to express foreign proteins (M. Singh and M. A. Billeter, J. Gen. Virol. 80:101-106, 1998). To develop an inexpensive MV-based vaccine, we generated recombinant MVs that produce structural proteins of hepatitis B virus (HBV). A recombinant virus that expressed the HBV small surface antigen (HBsAg) was analyzed in terms of its replication characteristics, its genetic stability in cell culture, and its immunogenic potential in genetically modified mice. Although this virus showed a progression of replication slightly slower than that of the parental MV, it appeared to stably maintain the added genetic information; it uniformly expressed the appropriately glycosylated HBsAg after 10 serial passages. Genetically modified mice inoculated with this recombinant MV produced humoral immune responses against both HBsAg and MV proteins.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10233943      PMCID： PMC112525     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  24 in total

1.  Measles antibody: reevaluation of protective titers.

Authors:  R T Chen; L E Markowitz; P Albrecht; J A Stewart; L M Mofenson; S R Preblud; W A Orenstein
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Preferential expression of the large hepatitis B virus surface antigen gene by an adenovirus-hepatitis B virus recombinant.

Authors:  T Yuasa; K Kajino; I Saito; T Miyamura
Journal:  J Gen Virol       Date:  1991-08       Impact factor: 3.891

Review 3.  Assembly and antigenicity of hepatitis B virus core particles.

Authors:  M Seifer; D N Standring
Journal:  Intervirology       Date:  1995       Impact factor: 1.763

4.  Recombinant measles viruses defective for RNA editing and V protein synthesis are viable in cultured cells.

Authors:  H Schneider; K Kaelin; M A Billeter
Journal:  Virology       Date:  1997-01-20       Impact factor: 3.616

5.  A recombinant measles virus expressing biologically active human interleukin-12.

Authors:  M Singh; M A Billeter
Journal:  J Gen Virol       Date:  1999-01       Impact factor: 3.891

6.  The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants.

Authors:  G D Hussey; E A Goddard; J Hughes; J J Ryon; M Kerran; E Carelse; P M Strebel; L E Markowitz; J Moodie; P Barron; Z Latief; R Sayed; D Beatty; D E Griffin
Journal:  J Infect Dis       Date:  1996-06       Impact factor: 5.226

7.  The human CD46 molecule is a receptor for measles virus (Edmonston strain).

Authors:  R E Dörig; A Marcil; A Chopra; C D Richardson
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

8.  Measles virus spread and pathogenesis in genetically modified mice.

Authors:  B Mrkic; J Pavlovic; T Rülicke; P Volpe; C J Buchholz; D Hourcade; J P Atkinson; A Aguzzi; R Cattaneo
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus.

Authors:  D Naniche; G Varior-Krishnan; F Cervoni; T F Wild; B Rossi; C Rabourdin-Combe; D Gerlier
Journal:  J Virol       Date:  1993-10       Impact factor: 5.103

10.  Rescue of measles viruses from cloned DNA.

Authors:  F Radecke; P Spielhofer; H Schneider; K Kaelin; M Huber; C Dötsch; G Christiansen; M A Billeter
Journal:  EMBO J       Date:  1995-12-01       Impact factor: 11.598
View more
  41 in total

1.  Polyploid measles virus with hexameric genome length.

Authors:  Monika Rager; Sompong Vongpunsawad; William Paul Duprex; Roberto Cattaneo
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

2.  Recombinant measles viruses efficiently entering cells through targeted receptors.

Authors:  U Schneider; F Bullough; S Vongpunsawad; S J Russell; R Cattaneo
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Mutations in the putative HR-C region of the measles virus F2 glycoprotein modulate syncytium formation.

Authors:  Richard K Plemper; Richard W Compans
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

4.  Extent of measles virus spread and immune suppression differentiates between wild-type and vaccine strains in the cotton rat model (Sigmodon hispidus).

Authors:  Joanna Pfeuffer; Karen Püschel; Volker ter Meulen; Jürgen Schneider-Schaulies; Stefan Niewiesk
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice.

Authors:  B Mrkic; B Odermatt; M A Klein; M A Billeter; J Pavlovic; R Cattaneo
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis.

Authors:  Tanner S Miest; Koon-Chu Yaiw; Marie Frenzke; Johanna Lampe; Andrew W Hudacek; Christoph Springfeld; Veronika von Messling; Guy Ungerechts; Roberto Cattaneo
Journal:  Mol Ther       Date:  2011-05-24       Impact factor: 11.454

Review 7.  Multivalent and Multipathogen Viral Vector Vaccines.

Authors:  Katharina B Lauer; Ray Borrow; Thomas J Blanchard
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

8.  Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.

Authors:  Amando Zuniga; Mathias Liniger; Teldja Neige Azzouz Morin; René R Marty; Marian Wiegand; Orhan Ilter; Sara Weibel; Martin A Billeter; Marlyse C Knuchel; Hussein Y Naim
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

9.  A molecularly cloned Schwarz strain of measles virus vaccine induces strong immune responses in macaques and transgenic mice.

Authors:  Chantal Combredet; Valérie Labrousse; Lucile Mollet; Clarisse Lorin; Frédéric Delebecque; Bruno Hurtrel; Harold McClure; Mark B Feinberg; Michel Brahic; Frédéric Tangy
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 10.  Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development.

Authors:  L Jean Patterson; Marjorie Robert-Guroff
Journal:  Expert Opin Biol Ther       Date:  2008-09       Impact factor: 4.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.